Aarhus University Seal / Aarhus Universitets segl

CYP2C19*2 and CYP2C19*17 variants and effect of tamoxifen on breast cancer recurrence: Analysis of the International Tamoxifen Pharmacogenomics Consortium dataset

Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaperJournal articleResearchpeer-review

  • Per Damkier, Univ Southern Denmark, Odense University Hospital, University of Southern Denmark, Dept Orthopaed Surg & Traumatol, Odense Univ Hosp, Inst Clin Res
  • ,
  • Anders Kjaersgaard
  • Kimberly A. Barker, Boston Univ, Boston University, Sch Med, Dept Microbiol
  • ,
  • Deidre Cronin-Fenton
  • Anatasha Crawford, Emory Univ, Emory University, Winship Canc Inst
  • ,
  • Ylva Hellberg, Aarhus Univ Hosp, Aarhus University, Dept Pathol
  • ,
  • Emilius A. M. Janssen, Stavanger Univ Hosp, Dept Pathol
  • ,
  • Carl Langefeld, Wake Forest Sch Med, Wake Forest University, Dept Biostat Sci
  • ,
  • Thomas P. Ahern, Univ Vermont, University of Vermont, Robert Larner MD Coll Med, Dept Surg, Univ Vermont, University of Vermont, Dept Biochem, Robert Larner MD Coll Med
  • ,
  • Timothy L. Lash

The role of cytochrome P450 drug metabolizing enzymes in the efficacy of tamoxifen treatment of breast cancer is subject to substantial interest and controversy. CYP2D6 have been intensively studied, but the role of CYP2C19 is less elucidated, and we studied the association of CYPC19 genotype and recurrence of breast cancer. We used outcome and genotyping data from the large publicly available International Tamoxifen Pharmacogenomics Consortium (ITPC) dataset. Cox regression was used to compute the hazard ratios (HRs) for recurrence. CYP2C19 genotype data was available for 2 423 patients and the final sample cohort comprised 2 102 patients. CYP2C19*2 or *19 alleles did not influence DFS. For the CYP2C19*2 allele, the HR was 1.05 (CI 0.78-1.42) and 0.79 (CI 0.32-1.94) for hetero-and homozygote carriers, respectively. The corresponding HR for hetero-and homozygote carriers of the CYP2C19*17 allele were 1.02 (CI 0.71-1.46) and 0.57 (CI 0.26-1.24), respectively. Accounting for CYP2D6 genotype status did not change these estimates. We found no evidence to support a clinically meaningful role of CYP2C19 polymorphisms and response to tamoxifen in breast cancer patients and, consequently, CYP2C19 genotype status should not be included in clinical decisions on tamoxifen treatment.

Original languageEnglish
Article number7727
JournalScientific Reports
Volume7
Number of pages8
ISSN2045-2322
DOIs
Publication statusPublished - 10 Aug 2017

    Research areas

  • DISEASE-FREE SURVIVAL, ADJUVANT TAMOXIFEN, CYP2D6 GENOTYPE, GENETIC POLYMORPHISMS, PERSONALIZED MEDICINE, CYP2C19 POLYMORPHISMS, HUMAN LIVER, METABOLISM, THERAPY, TRIAL

See relations at Aarhus University Citationformats

ID: 121660875